〇Takuya Ishibashi1, Tesshu Hori3, Keishun Iwao2, Hironobu Shuto3, Shouhei Ikuta6, Satoko Hattori4, Keizo Takao5,9,8, Tsuyoshi Miyakawa4, Chieko Koike1,2,3,7
(1.Ritsumeikan Global Innovation Research Organization, Ritsumeikan Univ, Shiga, Japan , 2.College Pharm Sci, Ritsumeikan Univ, Ritsumeikan Univ, Shiga, Japan , 3.Grad Sch Pharm, Ritsumeikan Univ, Ritsumeikan Univ, Shiga, Japan , 4. Inst Comp Med Sci Fujita Health University, Toyoake, Aichi, Japan, 5. Facult Med, Univ of Toyama, Toyama, Japan, 6.Grad Sch Life Sci, Ritsumeikan Univ, Ritsumeikan Univ, Shiga, Japan , 7.Cent for System Vision Sci, Res Org Sci Tech, Ritsumeikan Univ, Ritsumeikan Univ, Shiga, Japan , 8.Org for Promo of Res, Univ of Toyama,Toyama, Japan, 9.Res Cent Idling Brain Sci, Univ of Toyama,Toyama, Japan)
Keywords:Transient Receptor Potential Melastatin 1 (TRPM1), ON Bipolar cell, hyperactivity, 15q13.3 microdeletion syndrome